# Next Generation Sequencing Market

> Next Generation Sequencing Market Research Report: Size, Share, Trend Analysis By Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Single-Molecule Real-Time Sequencing, Nanopore Sequencing, Other Technologies), By Product Type (Reagents, Instruments, Software, Services), By Applications (Diagnostics, Research, Personalized Medicine, Agrigenomics), By End Use (Academic Institutes, Pharmaceutical Companies, Biotechnology Companies, Hospitals and Clinics) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 14.7%
- **2025:** USD 11.02 Billion
- **2035:** USD 42.61 Billion
- **Key Players:** Illumina, Inc., Thermo Fisher Scientific, BGI Genomics / MGI Tech, F. Hoffmann-La Roche AG, QIAGEN N.V., Oxford Nanopore Technologies, Pacific Biosciences, Agilent Technologies

**Report ID:** MRFR/HC/4893-HCR · **Pages:** 200 · **Author:** Rahul Gotadki & Nidhi Mandole · **Last Updated:** August 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/next-generation-sequencing-market-6354

---

## Market Summary

According to MRFR analysis, the Next Generation Sequencing Market Size was valued at USD 14.68 Billion in 2024. The market is projected to grow from USD 16.37 Billion in 2025 to USD 48.81 Billion by 2035, registering a CAGR of 11.54% during the forecast period (2025–2035). North America led the market with over 44.96% share, generating around USD 6.6 billion in revenue.
 
The Next Generation Sequencing Market is expanding rapidly due to increasing demand for genomic research and precision medicine. Key trends include declining sequencing costs, advancements in high-throughput sequencing technologies, and growing applications in cancer diagnostics, genetic disorder detection, and personalized medicine, driving adoption across research and clinical settings.

## Market Drivers

## Driver Impact Analysis

Impact percentages express each driver's directional contribution to headline growth. They are modelled independently and should not be summed against the 14.7% CAGR; overlapping effects and offsetting restraints are reconciled separately in the composite forecast.

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Precision oncology and companion diagnostics | +2.6 | North America, Europe, Japan | Medium-term (2–4 yr) | [8] |
| National population genomics programmes | +2.1 | UK, EU, China, Gulf, India | Long-term (≥4 yr) | [17] |
| Falling cost per genome and open chemistry | +1.9 | Global | Short-term (≤2 yr) | [2] |
| Reimbursement expansion for genomic profiling | +1.5 | US, Japan | Medium-term (2–4 yr) | [8] |
| Rare disease and newborn screening adoption | +1.3 | Europe, Asia-Pacific | Long-term (≥4 yr) | [3] |
| Biopharma multiomics R&D pipelines | +1.1 | Global | Medium-term (2–4 yr) | [9] |
| Pathogen genomic surveillance mandates | +0.8 | Global | Short-term (≤2 yr) | [16] |

### Precision Oncology Moves Into Standard of Care

Comprehensive genomic profiling has crossed from tertiary cancer centres into community oncology. The Centers for Medicare & Medicaid Services national coverage determination for sequencing-based cancer diagnostics established reimbursement for FDA-approved companion diagnostics in advanced solid tumours, converting a discretionary test into a billable one [[8]](https://www.cms.gov). That single policy shift underwrites much of the Next Generation Sequencing Market's clinical volume growth, and hospital pathology departments now run panel workflows on fixed weekly schedules rather than batching for cost efficiency.

### Sovereign Genomics Programmes Anchor Baseline Demand

Public commitments have created a demand floor insulated from research funding cycles. The European Union's 1+ Million Genomes initiative brought together participating member states around cross-border genomic data access [[17]](https://digital-strategy.ec.europa.eu), while Genomics England's Generation Study began sequencing newborns at population scale in late 2024 [[3]](https://www.genomicsengland.co.uk). India's GenomeIndia project completed reference sequencing across thousands of individuals spanning the country's population groups [[20]](https://dbtindia.gov.in). Procurement under these programmes runs on multi-year frameworks, giving suppliers revenue visibility that commercial channels rarely offer.

### Cost Curves Keep Rewriting the Addressable Base

Sequencing economics remain the strongest structural driver. NHGRI cost tracking shows per-genome pricing falling by orders of magnitude since 2008, far outpacing semiconductor cost curves [[2]](https://www.genome.gov). Each step down converts a previously uneconomic application — routine carrier screening, minimal residual disease monitoring, agricultural trait selection — into a viable one. Vendors offering open-chemistry instruments have accelerated this by unbundling reagents from hardware, pressuring proprietary ecosystem margins.

### Biopharma Rebuilds Discovery Around Sequence Data

Pharmaceutical R&D organisations have restructured target identification around large-scale genomic datasets. Roche, Thermo Fisher Scientific, and Qiagen each report sequencing-linked revenue growth tied to pharma service contracts and translational research programmes [[9]](https://ir.thermofisher.com)[[10]](https://www.roche.com)[[11]](https://corporate.qiagen.com). Single-cell and spatial workflows layered onto existing sequencers have raised reagent consumption per instrument without requiring new capital purchases.

## Restraints

## Restraints Impact Analysis

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Reagent supply chain and export-control exposure | −1.4 | Global; acute in China, US | Short-term (≤2 yr) | [21] |
| Coverage gaps outside oncology indications | −1.2 | Europe, Latin America | Medium-term (2–4 yr) | [8] |
| Bioinformatics and clinical genomics talent shortage | −1.0 | Global | Long-term (≥4 yr) | [15] |
| Genomic data privacy and localisation rules | −0.8 | EU, China, Gulf | Medium-term (2–4 yr) | [7] |
| Academic capital budget compression | −0.6 | North America, Europe | Short-term (≤2 yr) | [15] |

### Supply Chains Reclassified as Strategic Vulnerabilities

Trade policy has become a first-order commercial risk in the Next Generation Sequencing Market. Export controls administered through the U.S. Bureau of Industry and Security cover semiconductor components embedded in sequencing optics and flow-cell fabrication [[21]](https://www.bis.doc.gov), while China's countermeasures during 2025 restricted imports of certain foreign-manufactured sequencers. Laboratories running single-vendor fleets now face procurement committees demanding dual-sourcing plans before capital approval.

### Reimbursement Stops at the Oncology Boundary

Once you get beyond cancer testing, coverage is still spotty. [[7]](https://health.ec.europa.eu) Rare illness exome sequencing, pharmacogenomic panels and carrier screening are inconsistently treated by payers across European health systems, and IVDR conformity standards have increased the cost of compliance to bring assays to market. Laboratories thus either pay the cost of testing or restrict access, capping volume growth for indications where therapeutic usefulness is clearly established.

### Interpretation Capacity Lags Sequencing Capacity

The bottleneck is not in producing reads anymore, but in understanding them. OECD health workforce analysis indicates chronic shortages of specialized diagnostic roles in member nations [[15]](https://www.oecd.org), with clinical genomics being one of the tightest. Credentialed workers with training pipelines that can’t grow at instrument-shipment speed are needed for variant curation, tertiary analysis and reporting.

## Opportunities

## Next Generation Sequencing Market Opportunities

### Decentralised Clinical Sequencing at the Point of Care

On-cartridge library prep benchtop equipment, at under $50,000, open community hospitals and regional labs that could never finance a core facility. Vendors that place here trade instrument margin for ongoing consumable revenue, and the Next Generation Sequencing Market rewards that trade as placement density increases.

### Genomic Data Monetisation and Federated Analytics

Sequence data are valuable beyond the experiment that generated them. Biobank-pharma collaborations licensing access to de-identified cohorts have generated a services revenue stream separate from instrument sales, and federated architectures enable analysis without transferring data across borders – aligning commercial demand with localization rules.

### Emerging-Market Capacity Build-Out

Gulf states, Southeast Asia, and Latin America represent the clearest geographic gap. Saudi Arabia's national genome programme and comparable Emirati initiatives fund sequencing infrastructure alongside clinical training [[18]](https://www.kacst.gov.sa), and suppliers who bundle installation, informatics, and workforce development capture share that pure hardware bidders cannot.

### Multiomics Convergence on Existing Fleets

Spatial transcriptomics, single-cell profiling, and proteogenomic workflows run on installed sequencers, raising utilisation without new capital. This is the highest-margin growth vector available to incumbents in the Next Generation Sequencing Market.

### Carbon-Accounted Procurement

Public biobanks have begun embedding energy footprint per terabase into vendor scorecards. Suppliers who publish verified consumption data and reduce plastic consumable waste will win tenders on non-price criteria.

## Future Outlook

## Next Generation Sequencing Market Future Outlook

### Machine Learning Absorbs the Interpretation Layer

Variant calling and tertiary analysis are migrating to model-based pipelines that flag clinically actionable findings before human review. This compresses reporting turnaround and partially relieves the workforce constraint identified in Section 5.3. Vendors bundling validated informatics with instruments will defend pricing better than hardware-only competitors as the Next Generation Sequencing Market matures.

### Platform Economics Shift From Razor-Blade to Open Systems

Proprietary consumable lock-in delivered decades of margin. Open-chemistry entrants have broken that model in the mid-throughput tier, and reagent gross margins are compressing accordingly. Incumbents are responding with service contracts, informatics subscriptions, and application-specific kits rather than defending consumable exclusivity outright.

### Clinical Sequencing Displaces Research as the Volume Driver

Academic spending still leads share today, but clinical indications compound faster. Hereditary cancer risk, minimal residual disease monitoring, and prenatal screening each carry recurring test volumes tied to patient populations rather than grant cycles, shifting the demand base toward predictability by the early 2030s.

### Sustainability Reporting Enters Procurement Scoring

Public research funders have begun requiring supplier environmental disclosure. OECD health system analysis has raised laboratory resource efficiency as a policy concern [[15]](https://www.oecd.org), and biobanks are translating that into tender criteria covering energy per terabase and single-use plastic reduction. Suppliers without audited data will lose points before price is compared.

## Segment Insights

## Next Generation Sequencing Market Segmentation

Segmentation in the Next Generation Sequencing Market follows four commercially meaningful dimensions: type of sequencing, product type, application, and end user.

### By Type of Sequencing

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Targeted Resequencing | 35.4% share | Oncology panel volumes in hospital pathology |
| Whole Genome Sequencing | USD 2.71 Billion | Population cohorts and rare disease diagnosis |
| Whole Exome Sequencing | 15.2% CAGR (2026–2035) | Undiagnosed paediatric disease pathways |
| RNA Sequencing | 12.8% share | Transcriptomic profiling in drug discovery |
| ChIP Sequencing | USD 0.62 Billion | Epigenetic regulation research |
| Methyl Sequencing | 14.9% CAGR (2026–2035) | Early cancer detection assay development |

Targeted resequencing leads because it matches clinical workflow economics. Panels covering fifty to five hundred genes deliver actionable results at a price payers will reimburse, and turnaround fits treatment decision timelines. Whole exome sequencing grows fastest as diagnostic odysseys for rare disease shift toward broader first-line testing — Genomics England and comparable European programmes have demonstrated diagnostic yields that justify the incremental cost [[3]](https://www.genomicsengland.co.uk).

### By Product Type

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Reagents and Consumables | 65.0% share | Recurring run volume across installed fleets |
| Instruments | 15.4% CAGR (2026–2035) | Fleet replacement and benchtop decentralisation |
| Services | USD 1.34 Billion | Outsourced sequencing for biopharma and biobanks |

Consumables dominate revenue because installed instruments consume kits continuously, and this is where open-chemistry competition bites hardest. Instruments nonetheless grow fastest through 2035 as the replacement cycle for platforms purchased during the pandemic surveillance build-out arrives simultaneously with a new generation of benchtop systems priced for decentralised placement.

### By Application

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Drug Discovery and Personalized Medicine | USD 3.61 Billion | Target identification and patient stratification |
| Diagnostics | 24.1% share | Reimbursed oncology and infectious disease testing |
| Genetic Screening | 15.3% CAGR (2026–2035) | Newborn and carrier screening programmes |
| Agriculture and Animal Research | 12.3% share | Trait selection and livestock breeding |
| Reproductive Health and Other | 14.4% CAGR (2026–2035) | Non-invasive prenatal testing expansion |

Drug discovery and personalized medicine remain the dominant application within the Next Generation Sequencing market, driven by expanding adoption in target identification, companion diagnostics, and precision oncology trial stratification. Genetic screening is the fastest-growing application, propelled by scaled population initiatives, declining sequencing expenses, and broader clinical inclusion of routine carrier and newborn screening protocols.

### By End User

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Academics | 45.1% share | Grant-funded research and core facility capacity |
| Pharmaceutical and Biotechnology Companies | USD 3.04 Billion | Translational research and companion diagnostics |
| Hospitals and Healthcare Institutions | 15.6% CAGR (2026–2035) | In-house clinical sequencing adoption |
| Clinics and Other End Users | 6.9% share | Specialty testing and direct-to-consumer channels |

Academic institutions retain the largest share, but hospitals grow fastest as clinical laboratories bring testing in-house rather than sending specimens to reference providers. That transition depends on benchtop instrument economics and validated informatics arriving together — where either is missing, send-out models persist.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 38.9% share | Clinical reimbursement, oncology panels, biopharma R&D |
| Europe | USD 3.02 Billion | IVDR compliance, 1+MG cross-border data, rare disease |
| Asia-Pacific | 15.2% CAGR (2026–2035) | Domestic instruments, national cohorts, agrigenomics |
| South America | USD 0.51 Billion | Public health labs, oncology access expansion |
| Middle East & Africa | 3.3% share | Sovereign genome programmes, consanguinity screening |
| Total | USD 11.02 Billion | — |

Regional performance in the Next Generation Sequencing Market reflects the interaction of reimbursement depth, sovereign programme funding, and domestic manufacturing capability rather than population size alone.

### North America

| Country | Share of Region | Key Driver |
| --- | --- | --- |
| US | 84.5% | CMS coverage for genomic profiling in advanced cancers |
| Canada | 8.2% | Provincial rare disease sequencing programmes |
| Mexico | 7.3% | Private oncology laboratory network expansion |

The United States dominates the Next Generation Sequencing Market through payer infrastructure rather than instrument density alone. The FDA's laboratory developed test framework published in 2024 reshaped how reference laboratories validate assays [[6]](https://www.fda.gov), pushing volume toward platforms with regulatory clearance. Canada's provincial health systems fund exome sequencing for undiagnosed paediatric cases, while Mexican private hospital groups have built oncology panel capacity to serve cross-border demand.

### Europe

| Country | Share of Region | Key Driver |
| --- | --- | --- |
| Germany | 22.1% | University hospital genomics networks |
| UK | 19.4% | Generation Study and NHS Genomic Medicine Service |
| France | 13.6% | Plan France Médecine Génomique sequencing platforms |
| Italy | 9.2% | Regional oncology network consolidation |
| Spain | 7.1% | Rare disease reference centre designations |
| Nordic Countries | 8.4% | Population biobank linkage to health records |
| Russia | 4.3% | Domestic sequencing capacity substitution |
| Rest of Europe | 15.9% | EU cohesion funding for laboratory modernisation |

European demand is regulation-shaped. IVDR transition timelines have forced laboratories to replace in-house assays with conformity-assessed products or seek exemptions, concentrating spend on validated platforms [[7]](https://health.ec.europa.eu). Genomics England's newborn sequencing study represents the largest single clinical cohort commitment in the region [[3]](https://www.genomicsengland.co.uk), and Nordic biobanks continue to differentiate through registry linkage rather than raw volume.

### Asia-Pacific

| Country | Share of Region | Key Driver |
| --- | --- | --- |
| China | 33.8% | Domestic instrument manufacturing and provincial cohorts |
| Japan | 20.2% | AMED-funded genomic medicine and cancer gene panel coverage |
| India | 13.1% | GenomeIndia reference cohort and diagnostics affordability |
| South Korea | 10.4% | National bio big data project |
| ASEAN | 9.7% | Infectious disease surveillance networks |
| Rest of Asia-Pacific | 12.8% | Agrigenomics and livestock breeding programmes |

Asia-Pacific is the growth engine of the Next Generation Sequencing Market, and domestic supply is the reason. Chinese manufacturers have scaled ultra-high-throughput platforms that undercut imported systems on cost per gigabase, while Japan's AMED programmes fund genomic medicine implementation across designated core hospitals [[19]](https://www.amed.go.jp). India pairs the GenomeIndia reference dataset with a price-sensitive diagnostics sector that rewards benchtop economics [[20]](https://dbtindia.gov.in).

### South America

| Country | Share of Region | Key Driver |
| --- | --- | --- |
| Brazil | 54.9% | SUS oncology diagnostics and private laboratory chains |
| Argentina | 18.6% | Academic sequencing cores and rare disease networks |
| Rest of South America | 26.5% | Public health genomic surveillance capacity |

Brazil anchors regional demand through a two-tier structure: public system oncology testing at controlled prices alongside private laboratory networks serving insured populations. Currency volatility complicates capital purchases, pushing buyers toward reagent-rental and managed-service contracts. Surveillance infrastructure funded during the pandemic period has been repurposed for arbovirus and antimicrobial resistance monitoring across the region [[16]](https://www.who.int).

### Middle East & Africa

| Country | Share of Region | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 29.4% | National genome programme and consanguinity screening |
| UAE | 21.7% | Emirati Genome Programme and medical tourism diagnostics |
| South Africa | 18.3% | TB and HIV genomic surveillance platforms |
| Egypt | 11.2% | University hospital capacity expansion |
| Rest of MEA | 19.4% | Donor-funded pathogen sequencing networks |

Gulf sovereign programmes have compressed a decade of capacity building into a few procurement cycles. Saudi Arabia's national genome initiative, coordinated through state research institutions, funds instruments, informatics, and clinical training as a single package [[18]](https://www.kacst.gov.sa). Sub-Saharan demand is driven differently — pathogen sequencing networks built around tuberculosis and HIV drug resistance monitoring operate on donor budgets aligned to WHO surveillance strategy [[16]](https://www.who.int).

## Competitive Benchmarking

## Competitive Benchmarking

Concentration is moderate and softening. Estimated HHI sits near 1,650, with the top five suppliers holding roughly 62–70% of global revenue. A single incumbent still anchors the high-throughput tier, but open-chemistry entrants and Chinese manufacturers have fragmented the mid-throughput and regional segments materially since 2023. Revenue share ranges below are analyst estimates and will not sum precisely.

| Company | Est. Revenue Share Range | Key Offerings for Next Generation Sequencing Market | Strategic Positioning |
| --- | --- | --- | --- |
| Illumina, Inc. | ~34–40% | NovaSeq X series, NextSeq, MiSeq i100, DRAGEN informatics | Scale incumbent defending consumable ecosystem [1] |
| Thermo Fisher Scientific | ~10–13% | Ion Torrent Genexus, Oncomine assays, sample prep | Clinical workflow breadth and pharma services [9] |
| BGI Genomics / MGI Tech | ~7–10% | DNBSEQ platforms, ultra-high-throughput systems | Cost leadership; strongest in Asia-Pacific [14] |
| F. Hoffmann-La Roche AG | ~5–8% | Sequencing chemistry development, diagnostics portfolio | Re-entering platform tier via novel chemistry [10] |
| QIAGEN N.V. | ~4–6% | QIAseq panels, sample-to-insight workflows, informatics | Sample prep and interpretation specialist [11] |
| Oxford Nanopore Technologies | ~3–5% | MinION, GridION, PromethION long-read systems | Real-time, portable long-read differentiation [12] |
| Pacific Biosciences | ~2–4% | Revio and Vega HiFi long-read platforms | Accuracy-led long-read positioning [13] |
| Agilent Technologies | ~2–4% | SureSelect target enrichment, quality control systems | Enrichment and upstream workflow depth |
| Element Biosciences | ~1–3% | AVITI benchtop sequencing systems | Open-chemistry disruptor in mid-throughput tier |
| Ultima Genomics | ~1–2% | UG 100 high-scale sequencing platform | Ultra-low cost per genome for large cohorts |
| 10x Genomics | ~1–3% | Single-cell and spatial workflow solutions | Application layer riding installed sequencer base |
| Eurofins Genomics | ~1–3% | Outsourced sequencing and analysis services | Service-model access without capital outlay |

## Recent News & Developments

## Recent News & Developments

- Pacific Biosciences (2023): Commercial shipments of the Revio long-read system began, sharply increasing HiFi output per instrument and expanding long-read viability for population-scale projects [[13]](https://investor.pacb.com)
- MGI Tech (2023): Introduced ultra-high-throughput DNBSEQ systems positioned for national cohort programmes, intensifying cost-per-gigabase competition outside Western markets [[14]](https://www.bgi.com)
- Illumina (June 2024): Completed the separation of GRAIL as an independent public company, refocusing capital on core sequencing platforms and informatics [[1]](https://investor.illumina.com)
- U.S. FDA (May 2024): Published its final rule on laboratory-developed tests, phasing in device-framework oversight and reshaping validation economics for reference laboratories [[6]](https://www.fda.gov)
- Thermo Fisher Scientific (July 2024): Closed its acquisition of Olink, extending multiomics capability adjacent to sequencing workflows and deepening pharma research relationships [[9]](https://ir.thermofisher.com)
- Genomics England (October 2024): Launched the Generation Study to sequence newborn genomes at population scale, establishing the largest clinical newborn sequencing cohort to date [[3]](https://www.genomicsengland.co.uk)
- Roche (February 2025): Unveiled its sequencing-by-expansion chemistry, signalling a credible new entrant into the platform tier for the first time in over a decade [[10]](https://www.roche.com)
- China Ministry of Commerce (2025): Imposed restrictions affecting imports of certain foreign-manufactured sequencing instruments, accelerating domestic substitution across Chinese laboratories [[21]](https://www.bis.doc.gov)

## Frequently Asked Questions

**Q: What procurement criteria matter most when buying into the Next Generation Sequencing Market today?**
A: Total cost per sample matters more than instrument list price. Evaluate reagent contract terms, informatics licensing, service response guarantees, and whether the chemistry is open or proprietary. Dual-sourcing feasibility has become a standard requirement in institutional tenders [21].

**Q: How should buyers weigh short-read against long-read platforms?**
A: Short-read systems remain cheaper per base and suit panels, exomes, and resequencing. Long-read platforms resolve structural variants, repeat expansions, and phasing that short reads miss. Many well-funded labs now run both rather than choosing [12][13].

**Q: Is vendor lock-in still a material risk in the Next Generation Sequencing Market?**
A: Less than it was. Open-chemistry entrants have made mid-throughput fleets genuinely mixable, though informatics migration remains the harder switching cost. Negotiate data portability terms before signing multi-year reagent commitments.

**Q: What regulatory nuance most often surprises new clinical entrants?**
A: IVDR conformity assessment in Europe applies to in-house assays, not just commercial kits, and exemption conditions are narrower than many laboratories assume [7]. Budget compliance timelines of twelve to eighteen months before launch.

**Q: Which emerging application will scale fastest outside oncology?**
A: Newborn and carrier screening. Population programmes have moved from pilots to standing services, and per-test economics now clear reimbursement thresholds in several European systems [3].

**Q: How do integration challenges affect returns in the Next Generation Sequencing Market?**
A: Laboratory information system integration and variant curation capacity determine realised throughput far more than instrument specifications. Underinvesting here leaves expensive fleets running well below rated capacity [15].

**Q: What competitive shift should investors watch through 2028?**
A: Reagent gross margin compression at the incumbent tier. If open-chemistry share gains continue, the razor-blade model that funded a decade of platform R&D weakens, changing how new instrument development gets financed [1].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/next-generation-sequencing-market-6354*